Venture Capital

As China surpasses the US in key research metrics, a new English platform aims to bridge the information gap for global scientists and innovators.

A stark new benchmark study reveals poor survival in late-stage GvHD, just as MaaT Pharma’s microbiome therapy shows dramatically better outcomes.

Facing a severe cash crunch and delisting threats, the biotech firm is halting development and seeking buyers for its innovative cancer drug pipeline.

A Caltech spin-off just released a tiny AI model that's 14x smaller and 8x faster, putting powerful AI on your phone and slashing datacenter energy bills.

OBIO awards $100K to a cancer therapy startup and launches a new training program, directly addressing the systemic funding barriers for women in life sciences.

Responding to soaring AI and manufacturing demand, Cumming Group unifies 600+ specialists to build the world's most advanced high-tech facilities.

With key hires from Thoratec and Medtronic, CorWave signals an aggressive push to commercialize its revolutionary undulating membrane heart pump technology.

Amid record gold prices, Solomon Global's key sponsorship of the Master Investor Show highlights a major shift as investors seek stability in tangible assets.

Serenity Medical's River stent is a landmark approval for severe IIH, a condition causing chronic pain and vision loss, primarily in young women.

Philadelphia entrepreneur David Adelman brings his Darco Spirits portfolio to PA, a strategic move blending local pride with national market ambition.

Extell Development appoints Innovo founder Andrew Chung as Co-CEO, a move poised to reshape its capital strategy and diversify beyond luxury condos.

With its lead drug for a rare pediatric liver disease entering late-stage trials, NorthSea Therapeutics adds a veteran drug developer to its board.

Vaso Corporation posts a record $89.1M revenue for 2025, fueled by its GE HealthCare partnership after divesting its healthcare IT unit.

A new, imageable liver cancer therapy is one step closer to patients, thanks to a strategic partnership securing a vital US-based medical isotope supply.

A key U.S. patent extends protection for a promising CRPS-1 drug, paving the way for a potential first-in-class treatment for the debilitating condition.

Longhorn Diagnostics unveils LHNVD-501, a novel antibody targeting a universal bacterial component, offering a new front against AMR and chronic inflammation.

As homes shrink, creativity expands. Rockler's new DIY challenge, led by a YouTube star, inspires makers to build big in small spaces for major prizes.

A new partnership provides early access to an investigational drug for FAP, offering a potential non-surgical therapeutic option for the first time.

Ducted Vortex unveils a patented turbine using ancient principles, promising to solve wind and solar's biggest problems. Is it a revolution or just hype?

With trillions locked in private startups, Earlyasset emerges from stealth to build the financial 'plumbing' for a more liquid secondary market.